Rapport Therapeutics

RAPP on Nasdaq. Pharmaceutical preparations. Market value $1.6bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Not a fit for our list right now

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to September 2026
-8.8%low

For every $100 of what the whole company costs, it produced $-8.83 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: not known. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$23.16 a share, 5% above its 1-year low

Over the past year the price has ranged from $22.06 to $52.93.

Pays no dividend

Prices from Friday’s close (20 November).

Five years of cash, in billions

-0.1
-0.1
-0.1
2024202512 monthsto Sep '26
Revenue
n/an/a
Operating margin
n/an/a
Debt to equity
0.000.00
Shares outstanding
0.05bn0.06bn

Health checks

  • Free cash flow positive0 of 2 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)Not enough data
  • Profit backed by cash (accruals)Yes
  • Debt0.00× equity
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesNo, 24% more shares since 2024

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • A loss of $40 million, compared with a loss of $27 million a year ago.
  • Over the past 12 months it spent $121 million more cash than it brought in, compared with $78 million a year earlier.
  • 26% more shares than a year ago. Each share owns a bit less of the company.
  • It has $75 million more cash than debt, down from $251 million a year ago.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024Not reported
March 2025$0
June 2025$0
September 2025$0
December 2025Not reported
March 2026$20m
June 2026$0
September 2026$0
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024-$20m
March 2025-$24m
June 2025-$27m
September 2025-$27m
December 2025-$34m
March 2026-$20m
June 2026-$57m
September 2026-$40m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
10 March 2026
Next quarterly (estimated, 10-Q)
3 February 2027

Who owns it

None of the long-term investors we follow own it. 161 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

6 investors own more than 5%.

  • Third Rock Ventures V, L.P.
    Passive investor
    at least 13.1%−6.4 pts
    (filed with 5 related holders)
    Since 30 June 2026
  • Since 30 June 2026
  • at least 5.1%−0.4 pts
    (filed with 1 related holder)
    Since 30 September 2026
  • BlackRock, Inc.
    Passive investor
    5.0%
    Since 31 December 2025
  • JOHNSON & JOHNSON
    Passive investor
    at least 4.9%
    (filed with 1 related holder)
    Since 30 September 2025
  • Dr. James I. Healy ("Healy")
    Passive investor
    at least 4.2%
    (filed with 3 related holders)
    Since 11 September 2025
    What they said

    The Reporting Persons hold their securities of the Issuer for investment purposes. Depending on the factors discussed herein, the Reporting Persons may, from time to time, acquire additional Common Stock and/or retain and/or sell all or a portion of the Common Stock held by the…

    Read the filing

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 7 insiders bought $22m of shares on the open market. 4 sold $12m, $12m of it under preset trading plans.

Cluster buy7 insiders bought within 30 days (21 October 2026 to 28 October 2026).
  • HEALY JAMES
    Director
    Bought
    Date
    28 October 2026
    Shares
    969,480
    Price
    $21.00
    Value
    $20m
  • Sanchez Ramiro
    Director
    Bought
    Date
    23 October 2026
    Shares
    3,600
    Price
    $27.35
    Value
    $98,478
  • Silva Paul M
    Director
    Bought
    Date
    22 October 2026
    Shares
    3,680
    Price
    $27.07
    Value
    $99,636
  • Young Wendy B.
    Director
    Bought
    Date
    22 October 2026
    Shares
    3,789
    Price
    $26.39
    Value
    $99,992
  • PAUL STEVEN M
    Director
    Bought
    Date
    22 October 2026
    Shares
    35,714
    Price
    $27.28
    Value
    $974,278
  • MARAGANORE JOHN
    Director
    Bought
    Date
    22 October 2026
    Shares
    9,411
    Price
    $26.45
    Value
    $248,891
  • Ceesay Abraham
    Chief Executive Officer, Director
    Sold
    under a preset trading plan
    Date
    21 October 2026
    Shares
    2,210
    Price
    $29.16
    Value
    $64,448
  • Ignelzi Troy A.
    Chief Financial Officer
    Bought
    Date
    21 October 2026
    Shares
    5,500
    Price
    $26.10
    Value
    $143,550
  • Ceesay Abraham
    Chief Executive Officer, Director
    Sold
    under a preset trading plan
    Date
    7 October 2026
    Shares
    1,147
    Price
    $30.66
    Value
    $35,167
  • Ceesay Abraham
    Chief Executive Officer, Director
    Sold
    under a preset trading plan
    Date
    6 October 2026
    Shares
    3,375
    Price
    $32.03
    Value
    $108,106

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 10 Mar 2026, plus the 10-Q filed 4 Nov 2026 and 7 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.